epitinib (HMPL-813) / Hutchmed - LARVOL DELTA

Safety and Efficacy of Epitinib for EGFR-Mutant Non-Small Cell Lung Cancer With Brain Metastases: Open-Label Multicentre Dose-Expansion Phase Ib Study. (PubMed, Clin Lung Cancer) - P1 | "In patients with EGFR-mutant NSCLC with brain metastasis, epitinib was well tolerable with a promising efficacy. According to the comprehensive assessment on safety and efficacy, 160 mg QD could be the recommended phase 2 dose."

Journal • P1 data • Brain Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • EGFR

Chi-Med to present data from proof-of-concept clinical trials for fruquintinib and epitinib at the 17th World Conference on Lung Cancer ('WCLC') (Businesswire) - "Results from the positive Phase II third-line NSCLC clinical trial of fruquintinib...will be detailed in an oral presentation. Results from the ongoing Phase Ib first-line NSCLC clinical trial of epitinib...will also be presented."

Anticipated conference • Anticipated P1 data • Anticipated P2 data • Oncology

A Phase I Study of Epitinib(HMPL-813) in Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1; N=60; Recruiting; Sponsor: Hutchison Medipharma Limited; Trial primary completion date: Dec 2017 ➔ Jun 2019

Trial primary completion date • Biosimilar • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

HMPL-813 in Treating Patients With Glioblastoma (clinicaltrials.gov) - P1; N=29; Recruiting; Sponsor: Hutchison Medipharma Limited; Trial primary completion date: Dec 2019 ➔ Jun 2020

Clinical • Trial primary completion date

A Phase I Study of Epitinib(HMPL-813) in Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1; N=108; Completed; Sponsor: Hutchison Medipharma Limited; Active, not recruiting ➔ Completed; Trial completion date: Dec 2019 ➔ Apr 2019; Trial primary completion date: Sep 2019 ➔ Apr 2019

Clinical • Trial completion • Trial completion date • Trial primary completion date

HMPL-813 in Treating Patients With Glioblastoma (clinicaltrials.gov) - P1; N=29; Recruiting; Sponsor: Hutchison Medipharma Limited; Trial completion date: Aug 2019 ➔ Aug 2020; Trial primary completion date: Mar 2019 ➔ Dec 2019

Clinical • Trial completion date • Trial primary completion date

A Phase I Study of Epitinib(HMPL-813) in Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1; N=108; Active, not recruiting; Sponsor: Hutchison Medipharma Limited; Recruiting ➔ Active, not recruiting; N=60 ➔ 108

Enrollment change • Enrollment closed